Regression of Cardiac Rhabdomyomas in a Neonate after Everolimus Treatment


Cardiac rhabdomyoma often shows spontaneous regression and usually requires only close follow-up. However, patients with symptomatic inoperable rhabdomyomas may be candidates for everolimus treatment. Our patient had multiple inoperable cardiac rhabdomyomas causing serious left ventricle outflow-tract obstruction that showed a dramatic reduction in the size after everolimus therapy, a mammalian target of rapamycin (mTOR) inhibitor. After discontinuation of therapy, an increase in the diameter of masses occurred and everolimus was restarted. After 6 months of treatment, rhabdomyomas decreased in size and therapy was stopped. In conclusion, everolimus could be a possible novel therapy for neonates with clinically significant rhabdomyomas.

DOI: 10.1155/2016/8712962

Extracted Key Phrases

2 Figures and Tables

Showing 1-9 of 9 references


Citations per Year

108 Citations

Semantic Scholar estimates that this publication has received between 1 and 1,915 citations based on the available data.

See our FAQ for additional information.